Literature DB >> 22304910

FGF21 and the second coming of PPARγ.

Li Qiang1, Domenico Accili.   

Abstract

Peptide hormone fibroblast growth factor-21 (FGF21) has insulin-mimetic properties. Dutchak et al. now suggest that FGF21 also acts in an autocrine fashion in adipocytes and is required to mediate effects of the PPARγ agonist class of antidiabetic drugs. Does this new property improve FGF21's fledgling clinical prospects or endorse a clinical resuscitation of PPARγ agonists?
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22304910      PMCID： PMC3357185          DOI： 10.1016/j.cell.2012.01.020

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  9 in total

Review 1.  Glyceroneogenesis and the triglyceride/fatty acid cycle.

Authors:  Lea Reshef; Yael Olswang; Hanoch Cassuto; Barak Blum; Colleen M Croniger; Satish C Kalhan; Shirley M Tilghman; Richard W Hanson
Journal:  J Biol Chem       Date:  2003-06-04       Impact factor: 5.157

2.  Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

Authors:  Wolf Wente; Alexander M Efanov; Martin Brenner; Alexei Kharitonenkov; Anja Köster; George E Sandusky; Sabine Sewing; Iris Treinies; Heike Zitzer; Jesper Gromada
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

3.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma.

Authors:  Gabriel Pascual; Amy L Fong; Sumito Ogawa; Amir Gamliel; Andrew C Li; Valentina Perissi; David W Rose; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass
Journal:  Nature       Date:  2005-08-28       Impact factor: 49.962

4.  Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes.

Authors:  Hong Wang; Li Qiang; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

5.  Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

Authors:  Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman
Journal:  Nature       Date:  2010-07-22       Impact factor: 49.962

6.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.

Authors:  Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

7.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.

Authors:  Takeshi Inagaki; Paul Dutchak; Guixiang Zhao; Xunshan Ding; Laurent Gautron; Vinay Parameswara; Yong Li; Regina Goetz; Moosa Mohammadi; Victoria Esser; Joel K Elmquist; Robert D Gerard; Shawn C Burgess; Robert E Hammer; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

8.  Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.

Authors:  Eric S Muise; Barbara Azzolina; David W Kuo; Mohamed El-Sherbeini; Yejun Tan; Xiling Yuan; James Mu; John R Thompson; Joel P Berger; Kenny K Wong
Journal:  Mol Pharmacol       Date:  2008-05-08       Impact factor: 4.436

9.  Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

Authors:  Paul A Dutchak; Takeshi Katafuchi; Angie L Bookout; Jang Hyun Choi; Ruth T Yu; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582
  9 in total
  7 in total

1.  BACH2 inhibition reverses β cell failure in type 2 diabetes models.

Authors:  Jinsook Son; Hongxu Ding; Thomas B Farb; Alexander M Efanov; Jiajun Sun; Julie L Gore; Samreen K Syed; Zhigang Lei; Qidi Wang; Domenico Accili; Andrea Califano
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

2.  Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties.

Authors:  C Weidner; S J Wowro; A Freiwald; K Kawamoto; A Witzke; M Kliem; K Siems; L Müller-Kuhrt; F C Schroeder; S Sauer
Journal:  Diabetologia       Date:  2013-05-18       Impact factor: 10.122

3.  Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ.

Authors:  Li Qiang; Liheng Wang; Ning Kon; Wenhui Zhao; Sangkyu Lee; Yiying Zhang; Michael Rosenbaum; Yingming Zhao; Wei Gu; Stephen R Farmer; Domenico Accili
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

4.  Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway.

Authors:  Yong Zhou; Ying Wu; Yu Qin; Lei Liu; Jing Wan; Lingyun Zou; Qianyong Zhang; Jundong Zhu; Mantian Mi
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

5.  MiR-21-3p Inhibits Adipose Browning by Targeting FGFR1 and Aggravates Atrial Fibrosis in Diabetes.

Authors:  Jian-An Pan; Hao Lin; Jian-Ying Yu; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang; Jun Gu
Journal:  Oxid Med Cell Longev       Date:  2021-08-25       Impact factor: 6.543

6.  Factors associated with cognitive impairment in elderly versus nonelderly patients with metabolic syndrome: the different roles of FGF21.

Authors:  Arintaya Phrommintikul; Piangkwan Sa-Nguanmoo; Jirapas Sripetchwandee; Prin Vathesatogkit; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Sci Rep       Date:  2018-03-26       Impact factor: 4.379

7.  PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.

Authors:  Longhua Liu; Lihong Fan; Michelle Chan; Michael J Kraakman; Jing Yang; Yong Fan; Nicole Aaron; Qianfen Wan; Maria Alicia Carrillo-Sepulveda; Alan R Tall; Ira Tabas; Domenico Accili; Li Qiang
Journal:  Diabetes       Date:  2020-05-14       Impact factor: 9.337
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.